{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T11:37:54Z","timestamp":1780054674894,"version":"3.54.0"},"reference-count":33,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,11,10]],"date-time":"2025-11-10T00:00:00Z","timestamp":1762732800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Recurrent miscarriage is a distressing condition with limited therapeutic options. Chronic histiocytic intervillositis of unknown etiology (CIUE) is a rare inflammatory placental disorder characterized by maternal immune cell infiltration of the intervillous space, fibrin deposition, and ischemic tissue damage, leading to pregnancy loss. The condition likely reflects an immune response against paternal alloantigens, with histopathological features resembling antibody-mediated rejection in solid organ transplantation. We investigated two women with recurrent CIUE-related pregnancy losses. Detailed immunological profiling included anti-human leukocyte antigen (HLA) antibody characterization, compatibility testing, and histopathological examination of previous placentas, as well as screening for other causes of recurrent pregnancy losses. Based on evidence of antibody-mediated alloimmune injury, we implemented a targeted immunosuppressive regimen derived from transplantation medicine, combining intravenous immunoglobulins (IVIG), tacrolimus, corticosteroids, and hydroxychloroquine, with close pregnancy monitoring. The first patient, after six consecutive CIUE-related pregnancy losses, underwent preconception desensitization and continued treatment throughout pregnancy. Early signs of placental dysfunction prompted therapy intensification, leading to delivery of a viable infant at 33 + 2 weeks. Placental histology showed only minor residual CIUE lesions. The second patient, with two pregnancy losses and a fetal demise from CIUE, began treatment at 6 weeks\u2019 gestation and delivered a healthy infant at 36 weeks. In both cases, therapy was generally well tolerated, with gestational diabetes as the main complication, and no major maternal or neonatal adverse events. These cases support the concept that CIUE represents a breakdown of maternal immune tolerance toward paternal antigens, mediated by fetal-specific anti-HLA antibodies\u2014akin to solid organ graft rejection. An immunosuppressive protocol adapted from transplantation medicine achieved two successful live births after multiple CIUE-related pregnancy losses. Targeting antibody-mediated alloimmunity may represent a promising therapeutic strategy for selected patients with recurrent miscarriages due to CIUE. Further studies are warranted to define optimal regimens and identify predictors of response.<\/jats:p>","DOI":"10.3389\/fimmu.2025.1693016","type":"journal-article","created":{"date-parts":[[2025,11,10]],"date-time":"2025-11-10T05:18:13Z","timestamp":1762751893000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Case Report: A novel approach to prevent chronic histiocytic intervillositis and recurrent pregnancy loss by targeting maternal alloimmunity"],"prefix":"10.3389","volume":"16","author":[{"given":"Mathilde","family":"Gavillet","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carole","family":"Gengler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helene","family":"Legardeur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monique","family":"Gannag\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jardena","family":"Puder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lydie","family":"Beauport","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice","family":"Panchaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel","family":"Rotman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denis","family":"Comte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Baud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dela","family":"Golshayan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,11,10]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00682-6","article-title":"Miscarriage matters: the epidemiological, physical, psychological, and economic costs of early pregnancy loss","volume":"397","author":"Quenby","year":"2021","journal-title":"Lancet"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.fertnstert.2019.11.025","article-title":"Definitions of infertility and recurrent pregnancy loss: a committee opinion","volume":"113","year":"2020","journal-title":"Fertil Steril"},{"key":"B3","doi-asserted-by":"publisher","first-page":"hoad002","DOI":"10.1093\/hropen\/hoad002","article-title":"ESHRE guideline: recurrent pregnancy loss: an update in 2022","volume":"2023","author":"Bender Atik","year":"2023","journal-title":"Hum Reprod Open"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.825075","article-title":"Chronic inflammatory placental disorders associated with recurrent adverse pregnancy outcome","volume":"13","author":"Cornish","year":"2022","journal-title":"Front Immunol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.753220","article-title":"Immunomodulatory therapy reduces the severity of placental lesions in chronic histiocytic intervillositis","volume":"8","author":"Brady","year":"2021","journal-title":"Front Med (Lausanne)"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.fertnstert.2017.05.001","article-title":"Maternal allo-recognition of the fetus","volume":"107","author":"Moffett","year":"2017","journal-title":"Fertil Steril"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1038\/ni1317","article-title":"Mother\u2019s little helpers: mechanisms of maternal-fetal tolerance","volume":"7","author":"Trowsdale","year":"2006","journal-title":"Nat Immunol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1007\/s43032-019-00101-9","article-title":"Upregulation of HLA-class I and II in placentas diagnosed with villitis of unknown etiology","volume":"27","author":"Enninga","year":"2020","journal-title":"Reprod Sci"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1007\/s44368-024-00002-3","article-title":"Immunological harmony: the dynamic influence of cellular and humoral immunity on pregnancy success","volume":"1","author":"Pandey","year":"2024","journal-title":"Discover Immun"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.797360","article-title":"Peptides derived from mismatched paternal human leukocyte antigen predicted to be presented by HLA-DRB1, -DRB3\/4\/5, -DQ, and -DP induce child-specific antibodies in pregnant women","volume":"12","author":"Niemann","year":"2021","journal-title":"Front Immunol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1111\/tan.14054","article-title":"Toward defining the immunogenicity of HLA epitopes: Impact of HLA class I eplets on antibody formation during pregnancy","volume":"96","author":"Honger","year":"2020","journal-title":"HLA"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1111\/ajt.12048","article-title":"Frequency and determinants of pregnancy-induced child-specific sensitization","volume":"13","author":"Honger","year":"2013","journal-title":"Am J Transplant"},{"key":"B13","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.ejogrb.2007.06.018","article-title":"Chronic villitis of unknown etiology","volume":"136","author":"Boog","year":"2008","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1016\/S0368-2315(06)76411-0","article-title":"Combining corticosteroid and aspirin for the prevention of recurrent villitis or intervillositis of unknown etiology","volume":"35","author":"Boog","year":"2006","journal-title":"J Gynecol Obstet Biol Reprod (Paris)"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1002\/eji.201948382","article-title":"Immune checkpoint molecules in pregnancy: Focus on regulatory T cells","volume":"50","author":"Zhang","year":"2020","journal-title":"Eur J Immunol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2009101065","article-title":"Preexisting donor-specific HLA antibodies predict outcome in kidney transplantation","volume":"21","author":"Lefaucheur","year":"2010","journal-title":"J Am Soc Nephrol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-6143.2009.02985.x","article-title":"Baseline donor-specific antibody levels and outcomes in positive crossmatch kidney transplantation","volume":"10","author":"Gloor","year":"2010","journal-title":"Am J Transplant"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.2350\/14-12-1582-OA.1","article-title":"Significance of C4d immunostaining in placental chronic intervillositis","volume":"18","author":"Bendon","year":"2015","journal-title":"Pediatr Dev Pathol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.V133779","article-title":"Acute humoral rejection in kidney transplantation: II. Morphology, immunopathology, and pathologic classification","volume":"13","author":"Mauiyyedi","year":"2002","journal-title":"J Am Soc Nephrol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"662.e1","DOI":"10.1016\/j.ajog.2021.06.051","article-title":"Chronic histiocytic intervillositis: manifestation of placental alloantibody-mediated rejection","volume":"225","author":"Benachi","year":"2021","journal-title":"Am J Obstet Gynecol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1097\/TP.0000000000003095","article-title":"Recommended treatment for antibody-mediated rejection after kidney transplantation: the 2019 expert consensus from the transplantion society working group","volume":"104","author":"Schinstock","year":"2020","journal-title":"Transplantation"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1097\/TP.0000000000005341","article-title":"Pregnancy after solid organ transplantation: review of the evidence and recommendations","volume":"109","author":"Katz-Greenberg","year":"2025","journal-title":"Transplantation"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1097\/01.ASN.0000145878.92906.9F","article-title":"Evaluation of intravenous immunoglobulin as an agent to lower allosensitization and improve transplantation in highly sensitized adult patients with end-stage renal disease: report of the NIH IG02 trial","volume":"15","author":"Jordan","year":"2004","journal-title":"J Am Soc Nephrol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1097\/00007890-200009270-00006","article-title":"Plasmapheresis and intravenous immune globulin provides effective rescue therapy for refractory humoral rejection and allows kidneys to be successfully transplanted into cross-match-positive recipients","volume":"70","author":"Montgomery","year":"2000","journal-title":"Transplantation"},{"key":"B25","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1056\/NEJMoa1414838","article-title":"Predictive value of the sFlt-1:PlGF ratio in women with suspected preeclampsia","volume":"374","author":"Zeisler","year":"2016","journal-title":"N Engl J Med"},{"key":"B26","doi-asserted-by":"publisher","first-page":"EVIDoa2200161","DOI":"10.1056\/EVIDoa2200161","article-title":"Circulating angiogenic factor levels in hypertensive disorders of pregnancy","volume":"1","author":"Thadhani","year":"2022","journal-title":"NEJM Evid"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1111\/aji.13373","article-title":"Chronic histiocytic intervillositis: A breakdown in immune tolerance comparable to allograft rejection","volume":"85","author":"Brady","year":"2021","journal-title":"Am J Reprod Immunol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1111\/ajt.15898","article-title":"The Banff 2019 Kidney Meeting Report (I): Updates on and clarification of criteria for T cell- and antibody-mediated rejection","volume":"20","author":"Loupy","year":"2020","journal-title":"Am J Transplant"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0016806","article-title":"A signature of maternal anti-fetal rejection in spontaneous preterm birth: chronic chorioamnionitis, anti-human leukocyte antigen antibodies, and C4d","volume":"6","author":"Lee","year":"2011","journal-title":"PloS One"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1111\/j.1537-2995.2009.02206.x","article-title":"The effect of previous pregnancy and transfusion on HLA alloimmunization in blood donors: implications for a transfusion-related acute lung injury risk reduction strategy","volume":"49","author":"Triulzi","year":"2009","journal-title":"Transfusion"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajog.2025.09.032","article-title":"Immune tolerance breakdown in pregnancy: transplantation parallels in chronic intervillositis and villitis of unknown etiology","author":"Hannoun","year":"2025","journal-title":"Am J Obstet Gynecol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.945543","article-title":"Chronic histiocytic intervillositis (CHI): current treatments and perinatal outcomes, a systematic review and a meta-analysis","volume":"13","author":"Moar","year":"2022","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.20944\/preprints202506.2391.v1","article-title":"Chronic histiocytic intervillositis: insights into immunopathogenesis and prospective treatments","author":"Bell-Ricketts","year":"2025"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1693016\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,10]],"date-time":"2025-11-10T05:18:14Z","timestamp":1762751894000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1693016\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,10]]},"references-count":33,"alternative-id":["10.3389\/fimmu.2025.1693016"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1693016","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,10]]},"article-number":"1693016"}}